HighField Bio

HighField Biopharmaceuticals is a clinical-stage biotechnology company specializing in the development of innovative therapeutics through advanced drug delivery systems. The company utilizes its proprietary liposomal and nanoparticle platforms to improve the therapeutic index of immuno-oncology agents and traditional chemotherapies. Its lead candidate, HFB3010, is a liposomal Interleukin-12 (IL-12) designed to provide sustained anti-tumor activity while minimizing systemic toxicity. HighField Bio's pipeline also includes several liposomal formulations of established cytotoxic agents targeting various solid tumors. With operations in both China and the United States, the company aims to address significant unmet needs in oncology. The company's technology focuses on high-efficiency drug loading and controlled release to optimize patient outcomes.